From “Undruggable” to Precision Targeting: A New Leap in KRAS-Targeted Cancer Therapy

In the field of targeted cancer therapy, KRAS was once a target that made researchers hesitate, bearing the label of “undruggable” for more than 30 years. But medical research never yields to obstacles. In 2013, the discovery of the Switch II allosteric pocket opened a targeting opportunity for the KRAS G12C mutation. The approval of the first G12C inhibitor brought the dawn of precision therapy to lung cancer patients. Today, drugs targeting the more prevalent and challenging G12D mutation have entered clinical development, extending hope to an even broader population of cancer patients. This decades-long scientific effort has not only rewritten the fate of KRAS, but has also marked a major technological breakthrough in oncology.

KRAS Biological Characteristics and Oncogenic Mechanisms

As a member of the RAS gene family, KRAS regulates cell proliferation and survival signaling through dynamic GTP/GDP cycling, maintaining cellular homeostasis. When hotspot mutations such as G12D, G12V, and G12C occur, KRAS becomes locked in the active GTP-bound state, continuously activating downstream pathways including RAF-MEK-ERK and PI3K-AKT-mTOR, thereby driving the development of malignant tumors such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).

Figure 1 Activated states of KRAS and their impact on signaling pathways Targeting KRAS in pancreatic cancer

The “Undruggable” Dilemma of KRAS

Due to its smooth surface and compact structure, the KRAS protein lacks distinct binding pockets suitable for small-molecule drugs, earning it the long-standing label of an “undruggable” target.

Since KRAS was identified as an oncogene in 1982, more than three decades of drug development efforts repeatedly failed to remove this label. Early research focused on directly inhibiting KRAS activity, without recognizing the potential of strategies such as allosteric regulation or covalent binding. In 2013, the team led by Kevan Shokat at the University of California discovered the Switch II allosteric pocket in KRAS G12C, enabling the development of covalent inhibitors. This breakthrough laid the foundation for KRAS-targeted therapies.

Breakthroughs in KRAS Targeting

In 2021 and 2022, the US FDA approved the first covalent KRAS G12C inhibitors, Sotorasib (AMG510) and Adagrasib (MRTX849), respectively. Subsequently, to overcome resistance, next-generation KRAS inhibitors based on innovative inhibitory strategies emerged, including Elironrasib (RMC-6291). As G12C research matured, attention shifted to the more common and more difficult KRAS G12D mutation, with agents such as MRTX1133 and RMC-9805 entering development. Beyond direct small-molecule KRAS G12D inhibitors, emerging approaches such as proteolysis-targeting chimeras (PROTACs) and RNAi-based biodegradable implants are advancing rapidly. In addition, pan-KRAS targeting strategies offer hope to a broader patient population, with agents such as BI-2865 and RMC-6236.

Figure 2 Preclinical and clinical drugs targeting the KRAS pathway KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond

Challenges of Multiple KRAS Resistance Mechanisms

① Mutation or amplification at the KRAS G12C site;

② Compensatory activation of homologous RAS isoforms;

③ Activation of downstream effector molecules;

④ Activating mutations of RET-RTKs and oncogenic fusion proteins;

⑤ Adaptive non-genetic mechanisms.

KRAS Mutations: Innovative Response Strategies

① Ternary complex technology: KRAS-ON inhibitors such as RMC-6236 directly target the GTP-bound active state and are not affected by RTK activation;

② PROTAC degraders: LC-2 achieves KRAS G12C-specific degradation by recruiting the VHL E3 ubiquitin ligase;

③ Immunotherapy combinations: Adagrasib combined with PD-1 inhibitors can increase MHC I expression;

④ Artificial intelligence assistance: The AI platform AIScaffold predicts repurposing potential of existing drugs such as Afatinib, accelerating inhibitor development.

Future KRAS research will focus on overcoming drug resistance and enhancing therapeutic efficacy. Through innovative intervention strategies, targeted therapy bottlenecks will be addressed and the treatment landscape for KRAS-mutant malignancies will be expanded. As understanding of KRAS oncogenic mechanisms and resistance pathways deepens, more highly selective and potent precision-targeted therapies are expected to enter the clinic, driving breakthroughs in cancer treatment and providing high clinical value options that support long-term survival benefits for patients with KRAS mutation-associated malignancies.

To promote the development of drugs targeting KRAS resistance, Kyinno Biotechnology has established multiple series of KRAS in situ edited cell lines and conducted in vivo tumorigenicity and efficacy validation. These models can be used for antitumor drug screening and related studies. Detailed information is provided below. We welcome you to contact us for more details.